Redeye comments on Idogen following its report for the third quarter of 2022. We also comment on the announced rights issue and the financial position of Idogen.
ANNONS
Redeye comments on Idogen following its report for the third quarter of 2022. We also comment on the announced rights issue and the financial position of Idogen.